EMED (Electromedical Technologies) Debt-to-Equity: -0.41 (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Electromedical Technologies Debt-to-Equity?

Electromedical Technologies EMED Debt-to-Equity is -0.41 as of Sep. 2024.

Electromedical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.45 Mil. Electromedical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.21 Mil. Electromedical Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-4.01 Mil. Electromedical Technologies's debt to equity for the quarter that ended in Sep. 2024 was -0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Electromedical Technologies's Debt-to-Equity or its related term are showing as below:

EMED's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Electromedical Technologies  (OTCPK:EMED) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Electromedical Technologies Debt-to-Equity Related Terms


Electromedical Technologies Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Electromedical Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Electromedical Technologies Debt-to-Equity Chart

Electromedical Technologies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
-1.13 -1.04 -2.17 -0.89 -0.59

Electromedical Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.59 -0.52 -0.54 -0.41

EMED vs DYNT, SONX, USAQ: Debt-to-Equity Comparison

For the Medical Devices subindustry, Electromedical Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Electromedical Technologies Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Electromedical Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Electromedical Technologies's Debt-to-Equity falls into.



Electromedical Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Electromedical Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Electromedical Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.41 mean?
Electromedical Technologies (EMED) has a Debt-to-Equity of -0.41 as of Sep. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Electromedical Technologies and its competitors.
Is Electromedical Technologies' Debt-to-Equity too high?
Electromedical Technologies' current Debt-to-Equity is -0.41.
How does Electromedical Technologies' Debt-to-Equity compare to DYNT and SONX?
Electromedical Technologies' Debt-to-Equity of -0.41 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Electromedical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Electromedical Technologies's current Debt-to-Equity is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Electromedical Technologies stock overvalued right now?
Electromedical Technologies (EMED) has a current Debt-to-Equity of -0.41. The current Debt-to-Equity is -0.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Electromedical Technologies (EMED), the current Debt-to-Equity is -0.41 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Electromedical Technologies Business Description

Address 10105 E. Via Linda, No. 103-300, Scottsdale, AZ, USA, 85258
Electromedical Technologies Inc is a Delaware-based bioelectronics manufacturing company. The company designs, develops, and markets FDA-cleared, non-invasive, and simple-to-use bioelectronics therapy medical devices that serve as drug-free alternatives for pain relief. The company's device provide immediate and long-lasting pain relief across the broadest range of ailments. It focuses on improving globalised wellness for people suffering from various painful conditions.